Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Colorectal cancer (CRC) is one of the most frequently occurring malignancy tumors with a
high morbidity additionally, CRC patients may develop liver metastasis, which is the major …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis,
evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …